# Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference
Canonical URL: https://biopharmsignal.com/news/ALT/altimmune-to-participate-in-the-piper-sandler-37th-annual-healthcare-conference-fc2f17f6
Ticker: ALT
Company: Altimmune
Source: Altimmune
Published: 2025-11-26 12:30 EST
## Summary

Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel...

## Article Body
Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company’s management team will participate in a fireside chat at the Piper Sandler 37 th Annual Healthcare Conference. Details are as follows:

Conference: Piper Sandler 37 th Annual Healthcare Conference Date/Time: Wednesday, December 3, 2025 at 2:30 p.m. ET

The session will be webcast and can be accessed by visiting the Events section of the Altimmune website.

About Altimmune

Altimmune is a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company’s lead product candidate is pemvidutide, a glucagon/GLP-1 dual receptor agonist for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). For more information, please visit www.altimmune.com .

Follow @Altimmune, Inc. on LinkedIn Follow @AltimmuneInc on X

Investor Contact: Lee Roth Burns McClellan Phone: 646-382-3403 lroth@burnsmc.com

Media Contact: Savannah Valade Real Chemistry altimmune@realchemistry.com

This press release was published by a CLEAR® Verified individual.
## Recent Company News
- 2026-07-28 11:00 EST — [Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder](https://biopharmsignal.com/news/ALT/altimmune-announces-positive-topline-results-from-reclaim-phase-2-trial-of-pemvi-1fc61fa7) — Source: Altimmune
- 2026-05-28 15:00 EST — [Pemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48‑Week IMPACT Phase 2b Data Presented at EASL 2026](https://biopharmsignal.com/news/ALT/pemvidutide-demonstrates-significant-metabolic-improvements-in-patients-with-mas-a943260b) — Source: Altimmune
- 2026-05-27 12:30 EST — [Altimmune to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/ALT/altimmune-to-participate-in-upcoming-investor-conferences-90ad12d9) — Source: Altimmune
- 2026-05-27 12:00 EST — [New IMPACT Phase 2b Data Highlight Concurrent Improvements Across Multiple Non-Invasive Markers and qFibrosis-Measured Fibrosis Regression with Pemvidutide in MASH at EASL 2026](https://biopharmsignal.com/news/ALT/new-impact-phase-2b-data-highlight-concurrent-improvements-across-multiple-non-i-c3ed7d9e) — Source: Altimmune
- 2026-05-13 11:30 EST — [Altimmune Announces First Quarter 2026 Financial Results and Business Update](https://biopharmsignal.com/news/ALT/altimmune-announces-first-quarter-2026-financial-results-and-business-update-8b5f5558) — Source: Altimmune
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)